Dover DOV
Industrials · Industrial - Machinery · Synthos Deep Dive · 2026-07-03
The Overview
Dover is a diversified manufacturer — it makes a huge range of industrial gear: fuel-station and EV-charging equipment, refrigeration cases for supermarkets, pumps, product-marking and coding machines, and automation parts. Think of it as five different mid-sized machine companies bundled under one roof, which smooths out the bumps when any one market slows.
The business is solid and financially healthy — low debt, steady cash generation, and management is shifting the mix toward faster-growing niches (clean-energy fueling, biopharma pumps, CO2 refrigeration). But the stock is priced about fairly: you're paying roughly $20 for every $1 of next year's expected profit, which is reasonable but not a bargain, and the underlying business only grows sales about 5% a year.
Our verdict is Watch — a quality company we'd happily own on a pullback, but not cheap enough today to chase.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly low). Low debt and a diversified mix make it sturdy, but it's an industrial company, so a recession would hurt profits and the share price.
- Growth Quality 6/10 (good, not great). Profits grow at a healthy low-double-digit clip, helped by better product mix and share buybacks, but sales growth is only middling.
- Exponential Potential 3/10 (low). It's a mature, ~$29B company growing steadily — a compounder, not a rocket. Don't expect it to double quickly.
The one big worry: Dover's customers are factories, fuel retailers, and supermarkets. When the economy slows and businesses stop spending on equipment, Dover's orders and profits fall — and the stock usually falls faster.
Putting a number on it: our fair-value estimate is $235 against a current price of $198.68 — real upside if our numbers are right.
Our summary metrics
Low leverage (net-debt/EBITDA 0.9×) & 20× forward, but industrial cyclicality and beta 1.17.
~10-12% forward EPS CAGR on ~5% revenue growth; margins & mix improving, ROIC ~9%.
Mature $29B industrial compounder; ~5% top-line, no acceleration — steady, not exponential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature $29B industrial compounder; ~5% top-line, no acceleration — steady, not exponential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $242.73 (high $279 / low $205; median $250; 18 Buy · 10 Hold · 0 Sell) — context, not our anchor |
| Valuation | 26.5× trailing EPS · ~20× FY26E · ~18× FY27E · ~15× FY29E · EV/S 3.7× · EV/EBITDA 16.2× |
| Technicals | Mixed — $213.71, −8.4% off 52-wk high, below 50-DMA, above 200-DMA, RSI 45, +14.8% 12-mo (SPY +20.6%) |
| Conviction | Low — 0 Synthos KB claims (no expert coverage); call rests on fundamentals + quant |
| Position sizing | If owned, a ~1-3% diversified-industrial holding; not a high-conviction overweight |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for DOV — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $198.68, 6% below the 50-day average ($211), 5% below the 200-day average ($210) — a downtrend. 15% below the 52-week high of $233, 23% above the 52-week low of $161.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $198.68 is currently inside the band (band $198–$213).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 38.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.25, negative momentum.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = DOV · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Dover Corporation (NYSE: DOV) is a ~78-year-old diversified global manufacturer headquartered in Downers Grove, Illinois, with ~24,000 employees. It supplies industrial equipment, components, consumables, aftermarket parts, and software/digital platforms across five operating segments. CEO Richard J. Tobin has led a portfolio re-shaping toward higher-growth, higher-margin secular end markets. Fiscal year ends December 31.
Revenue mix (FY2025, from FMP segmentation):
| Segment | FY25 Revenue | ~% of total | What it does |
|---|---|---|---|
| Clean Energy & Fueling | $2.13B | 26% | Fuel-station & EV-charging hardware, cryo/hydrogen components, retail-fueling systems |
| Pumps & Process Solutions | $2.15B | 27% | Specialty pumps, connectors, biopharma single-use, polymer processing, thermal connectors |
| Climate & Sustainability Technologies | $1.56B | 19% | Commercial refrigeration cases/doors, CO2 systems, heat exchangers |
| Imaging & Identification | $1.17B | 15% | Marking & coding, serialization, brand protection, digital textile printing |
| Engineered Products | $1.09B | 13% | Vehicle-service (aftermarket), waste handling, industrial automation, aerospace/defense |
- By geography (FY25): United States $4.40B (~54%) · Europe $1.77B · Asia $0.90B · Americas ex-US $0.71B · Other $0.32B. A little over half US, meaningfully diversified internationally.
The strategic through-line management emphasizes: rotating capital toward secular-growth-exposed end markets — clean-energy/hydrogen fueling, biopharma/single-use pumps, CO2 refrigeration, and thermal-connector components tied to data-center cooling — while keeping the cyclical legacy base as a cash engine.
2. The expert thesis (no expert coverage)
There is no expert coverage of Dover in the Synthos knowledge base: total_claims = 0, breadth = 0, net conviction = 0. No net-bullish or cautionary voices have been distilled for this name. That is an honest gap, not a hidden signal — Dover is a quality mid-cap industrial that simply has not surfaced in the podcast/interview corpus the Synthos KB is built from.
Consequently, this verdict is entirely fundamentals- and quant-driven. Every number below traces to the FMP financials, analyst-estimate, and price data (labeled where forward/estimated) or to management's own SEC 8-K earnings release (§9, half-weighted). We cite zero claim_id values because there are zero claims — fabricating conviction here would violate the house standard.
The external read we can cite is the sell-side, offered as context only: 18 Buy / 10 Hold / 0 Sell, consensus rating "Buy," price-target consensus $242.73 (median $250, high $279, low $205). FMP's letter rating is B (overall score 3/5). We treat these as context, not as our anchor.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Low-Moderate | Net-debt/EBITDA 0.88×, interest coverage 12×, current ratio 1.87 — a sturdy balance sheet. Offsets: beta 1.17, industrial cyclicality, and ~20× forward leaves modest cushion. |
| Growth Quality | 6 · Good | Forward EPS CAGR ~10-12% (FY25 ~$8.01 → FY29E $14.25) on ~5% revenue growth; gross margin 39.5% and rising, ROIC ~9.4%, ROE 14.7%. Quality mix shift, but top-line is modest. |
| Exponential Potential | 3 · Low | ~5% revenue growth with no acceleration; mature $29B cap in a fragmented but slow-growing industrial TAM. A compounder, not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Secular-mix shift accelerates; organic growth pushes toward 6-7%; margins expand with productivity + M&A. FY27E EPS beats to ~$12.5; multiple re-rates to ~23× as the market pays up for the higher-quality mix. | ~$290 (+36%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS ~$11.7; a ~10-12% EPS compounder with improving mix earns a ~20× forward multiple. | ~$235 (+10%) |
| Bear | Industrial downturn: organic growth stalls or turns negative, margins give back gains; FY27E EPS misses to ~$10.3; multiple de-rates to ~17× on cyclical fear. | ~$175 (−18%) |
Synthos fair value = the base case, ~$235 (+10%), with the full $175–$290 span as the honest range. This anchor sits below the Street's $242.73 consensus — we are slightly less generous on the forward multiple than the sell-side. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). DOV is a solid compounder with low exponential potential:
- Forward growth: revenue CAGR FY25→FY29E ~5.4% ($8.09B → ~$9.98B est); EPS CAGR ~10-12% (adjusted continuing ~$8.01 → $14.25E) — the gap between the two is margin/mix improvement and buybacks, not unit volume.
- Acceleration (the 2nd derivative) is roughly flat: revenue growth was +4.5% (FY25) and estimates run ~7% (FY26E) → ~4.7% (FY27E) → ~4.1% (FY28E) → ~5.6% (FY29E). No sustained inflection — steady mid-single-digit organic. Per our flagship philosophy we favor forward accelerating names; DOV is a trailing/steady compounder, which is precisely why it scores low here.
- Room to run: at $28.8B market cap in a mature, fragmented industrial-machinery market, there is no large-TAM-vs-tiny-company mismatch to fuel a multibagger. Growth comes from bolt-on M&A and mix, not a category explosion.
- Reinvestment runway: disciplined — ~$220M/yr capex (2.8% of revenue) plus an active bolt-on acquisition pipeline (~$663M deployed FY25). Capital is returned via dividend (69 consecutive years of increases as a Dividend King) and opportunistic buybacks.
Exponential Potential: Low. Own DOV (if at all) for durable ~10-12% earnings compounding and a fortress balance sheet, not for a fast multibagger. This honest framing is why DOV is a Watch/diversified-holding candidate, not a satellite moonshot.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $8.09B, +4.5% (FY24 $7.75B, FY23 $7.68B). Steady mid-single-digit growth; Q1'26 revenue $2.05B, +10% reported / +5% organic (per management).
- Quarterly trajectory: Q1'25 $1.87B → Q2 $2.05B → Q3 $2.08B → Q4 $2.10B → Q1'26 $2.05B (+10% YoY). Consistent, not accelerating.
- Margins: gross 39.5% TTM (up from ~38% FY24), EBITDA margin 22.7% TTM, operating ~16.7%, net 13.3% TTM. The mix shift is slowly lifting gross margin.
- Earnings (mind the noise): FY25 GAAP net income $1.09B, diluted EPS $7.92 (adjusted continuing ~$8.01). Note: FY24's reported EPS of $19.58 is not comparable — it was inflated by a ~$1.3B after-tax gain on the De-Sta-Co/discontinued-operations divestiture. Use the ~$8/share continuing base, not the $19.58 headline.
- Cash flow: operating CF $1.34B FY25, capex −$220M, FCF $1.12B (FCF margin ~14%, FCF yield ~3.9%). High-quality earnings (income-quality 1.24).
- Balance sheet: total debt $3.78B, cash $1.68B, net debt $2.10B, net-debt/EBITDA 0.88× — conservative. Interest coverage 12.4×, current ratio 1.87. Goodwill+intangibles $7.19B (~54% of assets) is the one balance-sheet caveat — reflects an acquisitive history.
6. Valuation — priced in or room?
Dover is reasonably, not cheaply, valued. Trailing 26.5× EPS overstates richness because FY24's discontinued-ops gain distorts the trailing base; the cleaner read is forward: ~20× FY26E ($10.66), ~18× FY27E ($11.68), ~15× FY29E ($14.25). On enterprise value it is 16.2× EV/EBITDA and 3.7× EV/sales — a modest premium to the average diversified industrial, arguably warranted by the improving secular mix and 39.5% gross margin. FCF yield ~3.9%, dividend yield ~1.0% (payout only ~26%, so the dividend is very safe and growable). A reverse read: ~20× forward on a ~10-12% EPS grower implies a PEG near ~1.7-2.0 — full, not stretched. Street targets (context): consensus $242.73, high $279, low $205, median $250 — our $235 base FV sits just below consensus because we hold the forward multiple at ~20× rather than re-rating it. Not a value buy; a fairly-priced quality industrial.
7. Technicals (from the tech block)
- Trend: mixed. $213.71 sits below the 50-DMA ($218.62) but above the 200-DMA ($202.49) — a short-term stall inside a longer-term uptrend. MACD +1.25 (mildly positive).
- Location: −8.4% off the 52-week high ($233.31), +32.6% off the 52-week low ($161.16). Max drawdown from peak only −8.4% — an orderly pullback, not a breakdown.
- Momentum: RSI(14) 45 — neutral, neither overbought nor oversold. No stretched-entry signal either way.
- Relative strength (the tell): DOV +14.8% 12-mo vs SPY +20.6% and QQQ +30.3% — lagging both the market and (especially) growth. 3-mo +3.1% vs SPY +13.7%. This is a defensive-quality name that has trailed a growth-led tape.
- Read: technicals are neutral-to-slightly-soft — below the 50-DMA and lagging the index argues there's no urgency to chase. A hold of the 200-DMA (~$202) on any dip would be the constructive lower-risk entry.
8. Moat & competitive position
Dover's moat is breadth + niche leadership + aftermarket/consumables: within each segment it holds strong positions in specialized, application-engineered products (fuel-dispensing systems, marking/coding consumables, biopharma single-use, CO2 refrigeration) where switching costs and a recurring consumables/aftermarket tail create stickiness. The diversified five-segment structure smooths cyclicality — book-to-bill was above one in all five segments in Q1'26 per management. It is not a wide-moat monopoly; it competes with strong diversified-industrial peers and its ~54% goodwill/intangibles base reflects that growth has been partly bought.
Peer set (market cap, from FMP): Ingersoll Rand $31.5B (closest diversified-industrial comp), Curtiss-Wright $28.1B, Hubbell $25.7B, Veralto $22.7B, AerCap $23.3B, Equifax $20.8B, IDEX $16.6B, ITT $16.7B, Howmet $108B, Pentair $12.4B. DOV sits mid-pack on multiple and growth — neither the cheapest nor the fastest-growing of the group, which is consistent with the Watch verdict.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and shareholder-friendly — a Dividend King (69 consecutive years of dividend increases; payout only ~26%), opportunistic buybacks (~$541M repurchased FY25), ~$220M capex into high-ROI capacity, and ~$663M of bolt-on M&A in FY25. Net-debt/EBITDA held at a conservative ~0.9×.
- Insider activity: the only recent Form 4s in the window are routine "F-InKind" tax-withholding dispositions (CEO Tobin, Treasurer, CHRO, GC) tied to vesting on 2026-03-13 at $204.28 — administrative, not discretionary open-market selling. No alarming signal.
- Management's own guidance (the earnings-release track — half-weighted, self-interested): Dover's SEC 8-K (Q1'26 release, 2026-04-23) is a genuine earnings release. Management guides FY2026 GAAP EPS of $8.92–$9.12 (adjusted EPS $10.45–$10.65) on full-year revenue growth of 5%–7% (organic 3%–5%), and reiterated a commitment to "double-digit adjusted EPS growth at the midpoint" in 2026. CEO Tobin cited "excellent" bookings with book-to-bill above one in all five segments and an active acquisition pipeline. As management's own book, we half-weight it — but it corroborates the mid-single-digit-revenue / low-double-digit-EPS frame our base case uses.
10. Catalysts & what to watch
- Next earnings: 2026-07-23 (Q2'26; Street EPS $2.72, revenue ~$2.21B). Key line: organic growth and book-to-bill across the five segments — confirmation the Q1 order strength is holding.
- Bookings/backlog: management flagged book-to-bill above one in all five segments — watch whether that converts to accelerating organic revenue.
- Margin trajectory: continued gross-margin expansion from the secular-mix shift is the main EPS-quality lever.
- M&A: Tobin says the industrial-M&A pipeline is picking up — accretive bolt-ons are a core growth input; watch multiples paid.
- End-market cyclicals: fuel-retail capex, supermarket refrigeration replacement cycles, and biopharma capex are the swing macro exposures.
Thesis tripwires (what would change the call): two consecutive quarters of negative organic growth or book-to-bill below one; gross-margin reversal; a large, dilutive/expensive acquisition; or a multiple re-rating above ~23× that removes the remaining upside (a signal to trim, not add).
11. Key risks
- Industrial cyclicality (structural): roughly two-thirds of revenue is tied to customer capex and industrial demand; a recession compresses both earnings and the multiple — beta 1.17.
- Valuation cushion is thin: at ~20× forward on ~5% organic growth, there's limited margin for a demand or margin disappointment.
- Acquisition dependence / goodwill: ~54% of assets are goodwill+intangibles; growth relies partly on bolt-on M&A, carrying integration and impairment risk if a deal sours.
- End-market concentration within segments: exposure to fuel-retail transition (EV shift is both opportunity and threat to legacy fueling), supermarket capex cycles, and biopharma spending swings.
- No expert corroboration: unlike our conviction names, there is no independent expert panel in the KB to pressure-test the thesis — the call rests solely on fundamentals and quant.
12. Verdict, position sizing & monitoring
Watch. Dover is a genuinely well-run, low-leverage, quality diversified industrial (FY25 revenue $8.09B, FCF $1.12B, net-debt/EBITDA 0.9×, Dividend King, book-to-bill above one in all five segments) that is patiently upgrading its mix toward secular-growth markets. The problem is not the business — it's the price and the pace: at ~20× forward on ~5% organic growth, the stock is roughly fairly valued, our base FV (~$235, +10%) sits just under the Street's $242.73, and there is no expert conviction in the KB to lean on. That combination is a Watch, not a Buy.
- Sizing: if owned, a ~1-3% diversified-industrial/quality-compounder holding — not a high-conviction overweight. Better entries likely come on a hold of the 200-DMA (~$202) or an industrial-cycle scare.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-07-23). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $213.71.
- Single biggest risk: industrial cyclicality — a capex/demand downturn hits both earnings and the multiple, and there's limited valuation cushion.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert coverage exists for DOV in the Synthos knowledge base, so no
claim_ids are cited. This verdict is fundamentals- and quant-driven; fabricated conviction is structurally impossible (and here, explicitly absent). - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03. Forward figures are analyst consensus (FMP), labeled as estimates. Note FY24 reported EPS ($19.58) includes a one-time discontinued-operations gain and is not comparable to the ~$8 continuing-EPS base.
- Management caveat: the FY2026 guidance (adjusted EPS $10.45–$10.65; revenue growth 5–7%) is from Dover's own SEC 8-K earnings release — management's self-interested words, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").